$ACN

Accenture's Q4 Earnings Beat Estimates, Revenues Increase 6% Y/Y

Accenture reported Q4 2026 earnings of $3.29 per share, beating estimates by 3.1%, and revenues of $18.7B, up 6.2% Y/Y. Growth was broad-based across industries and regions. The company expects FY27 revenues of $18.95B-$19.60B and earnings of $14.39-$14.81 per share.

Original reporting
Published Oct 1, 2026, 3:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Accenture's Q4 Earnings Beat Estimates, Revenues Increase 6% Y/Y — source image
Decision brief

The 30-second read

$ACNBearishHigh
01

Why it matters

The earnings beat may generate short‑term buying, but the guidance miss is likely to outweigh the beat, leading to a net negative price impact.

02

Market read

First report of Accenture's earnings and guidance; material for traders due to size and market influence.

03

What to watch

Accenture's strong cash flow and share repurchase program may support the stock despite guidance miss.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

Accenture's Q4 FY2026 results were released, showing earnings of $3.29 EPS beating estimates and revenue of $18.7B beating estimates, with FY27 guidance slightly below consensus.

Company-level read

Ticker impact

$ACNBearishHigh confidence
Context

Accenture reported Q4 earnings beat and revenue beat but FY27 guidance below consensus, a fresh primary disclosure.

Expected impact

likely downside as market prices in weaker guidance

Evidence & confidence

Beat on EPS and revenue is positive, yet FY27 revenue and EPS guidance miss estimates, which typically drives the stock down.

Market effects

May weigh on broader consulting and professional services sector as peers face similar guidance pressures.

North America markets could see modest pullback in tech‑heavy indices.

Limited to firms with comparable business models; global impact minimal.

Counterpoint

The beat on earnings and revenue could signal operational strength; the guidance miss may be temporary, presenting a buying opportunity on dip.

Key entities

  • Accenture plc

    Global professional services firm reporting Q4 FY2026 results.

Related articles

$ACNHighAI 9/10

Accenture (ACN) Shares Surge 21% Following Strong Q4 Earnings Be

Accenture (ACN) shares rose 21% after Q4 earnings of $3.29 per share beat estimates by $0.11. Revenue grew 6.3% YoY to $18.7B, exceeding forecasts. The company offered optimistic guidance for 2027, with revenue growth projected between 3% and 6%. Accenture's dividend yield is 2.96% with a payout ratio of 47%, and it has a GF Score of 87, indicating strong financial health.

$ACNMed

Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more

Accenture rose 18% after Q4 revenue of $18.7B beat estimates. McCormick's Q3 results topped expectations but shares fell 2% amid Unilever's acquisition. McKesson gained 4% on reaffirmed guidance and a CVS Health partnership. United Therapeutics climbed 6% after a court ruling, while Liquidia dropped 15%. Constellation Energy gained 3% on a 20-year Amazon deal. Synopsys jumped 8% with 2027 revenue targets. Sigma Lithium slid 16% after halting production.